<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of homocysteine</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of homocysteine</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of homocysteine</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Rosenson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">C Christopher Smith, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth A Bauer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mason W Freeman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sara Swenson, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Homocysteine is an intermediary amino acid formed by the conversion of methionine to cysteine  (<a class="graphic graphic_figure graphicRef118333" href="/z/d/graphic/118333.html" rel="external">figure 1</a>). Homocystinuria is a rare autosomal recessive disorder characterized by severe elevations in plasma and urine homocysteine concentrations. Clinical manifestations of homocystinuria include developmental delay, Marfanoid appearance, osteoporosis, ocular abnormalities, thromboembolic disease, and severe premature atherosclerosis.</p><p>Less marked elevations in plasma homocysteine are much more common, occurring in 5 to 7 percent of the population [<a href="#rid1">1,2</a>]. Although unassociated with the clinical stigmata of homocystinuria, moderate hyperhomocysteinemia was considered an independent risk marker for atherosclerotic vascular disease and for venous thromboembolism (VTE). However, associations between plasma homocysteine and vascular complications, particularly VTE, may have been due to failure to take into account confounding risk factors. (See <a class="local">'Disease associations'</a> below.)</p><p>This topic will review hyperhomocysteinemia as a risk marker for vascular disease and whether or not to test for or treat elevated homocysteine levels.</p><p class="headingAnchor" id="H2"><span class="h1">ETIOLOGY OF HYPERHOMOCYSTEINEMIA</span><span class="headingEndMark"> — </span>Homocysteine is metabolized by one of two pathways: transsulfuration and remethylation  (<a class="graphic graphic_figure graphicRef118333" href="/z/d/graphic/118333.html" rel="external">figure 1</a>). Vitamins are necessary in the metabolism of homocysteine. The transsulfuration of homocysteine to cysteine is catalyzed by cystathionine-beta-synthase, a process that requires pyridoxal phosphate (vitamin B6) as a cofactor. Remethylation of homocysteine produces methionine. This reaction is catalyzed either by methionine synthase or by betaine-homocysteine methyltransferase. Vitamin B12 (cobalamin) is the precursor of methylcobalamin, which is the cofactor for methionine synthase.</p><p>Elevations in plasma homocysteine levels can result from:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic factors</strong> – The most common form of genetic hyperhomocysteinemia results from production of a thermolabile variant of methylene tetrahydrofolate reductase (<em>MTHFR</em>) with reduced enzymatic activity (T mutation)  (<a class="graphic graphic_figure graphicRef118333" href="/z/d/graphic/118333.html" rel="external">figure 1</a>) [<a href="#rid3">3</a>]. The responsible gene is common; in the United States, approximately 30 percent of the population is heterozygous for the thermolabile variant of <em>MTHFR</em> and 10 percent is homozygous [<a href="#rid4">4</a>]. Homozygosity for the thermolabile variant of <em>MTHFR</em> (TT genotype) is a relatively common cause of elevated plasma homocysteine levels in the general population, often occurring in association with low serum folate levels [<a href="#rid5">5-7</a>]. At any given level of folate intake, TT homozygotes have lower plasma folate levels than nonhomozygotes [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin deficiencies</strong> – Increased blood levels of homocysteine may reflect deficiency of folate, vitamin B6, or vitamin B12 [<a href="#rid9">9-12</a>]. Plasma folate and B12 levels, in particular, are strong determinants of the homocysteine concentration. Homocysteine levels are inversely related to folate consumption, reaching a stable baseline level when folate intake exceeds 400 microg/day [<a href="#rid13">13-15</a>]. Vitamin B6 is a weaker determinant of homocysteine levels [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1">The importance of vitamin deficiency in the pathogenesis of hyperhomocysteinemia was evaluated in a cohort of 1041 older adults [<a href="#rid13">13</a>]. Two-thirds of patients with elevated homocysteine levels had a subnormal plasma concentration of folate, vitamin B12, or pyridoxal-5-phosphate (the coenzyme form of vitamin B6). The prevalence of low plasma B12 levels was higher in this cohort than in a European case-control study with younger patients [<a href="#rid14">14</a>]. These data suggest that suboptimal B12 intake coupled with decreased absorption might play a greater role in elevating homocysteine and subsequent coronary heart disease (CHD) risk in older adults than in younger patients. By contrast, folate intake low enough to raise plasma homocysteine may be relatively common in the general population, particularly in moderate consumers of alcohol.</p><p></p><p class="bulletIndent1">Further evidence of the importance of vitamin deficiency comes from a report that assessed the results of the US Food and Drug Administration (FDA) regulation requiring all enriched grain products be fortified with <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a>. Patients who had blood tested following fortification had significantly higher blood folate concentrations and lower homocysteine concentrations [<a href="#rid16">16</a>]. In addition, the prevalence of a high homocysteine concentration (&gt;13 micromol/L) decreased from 18.7 percent before fortification to 9.8 percent after fortification.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic kidney disease</strong> – Chronic kidney disease can increase homocysteine levels due to decreased renal removal and impaired metabolism. (See  <a class="medical medical_review" href="/z/d/html/1962.html" rel="external">"Secondary prevention of cardiovascular disease in end-stage kidney disease (dialysis)", section on 'Hyperhomocysteinemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs</strong> – Some drugs used in the treatment of hypercholesterolemia, such as fibrates and nicotinic acid, can raise homocysteine levels by approximately 30 percent; however, the clinical significance of this is uncertain [<a href="#rid17">17-19</a>]. <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">Metformin</a> has also been associated with increases in homocysteine levels [<a href="#rid20">20</a>], as has <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smoking</strong> – Cigarette smoking may elevate homocysteine levels [<a href="#rid21">21</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h1">DISEASE ASSOCIATIONS</span><span class="headingEndMark"> — </span>Markedly elevated levels of homocysteine in the blood have primary atherogenic and prothrombotic properties [<a href="#rid2">2,22-38</a>]. Histopathologic hallmarks of homocysteine-induced vascular injury include intimal thickening, elastic lamina disruption, smooth muscle hypertrophy, marked platelet accumulation, and the formation of platelet-enriched occlusive thrombi [<a href="#rid39">39-43</a>]. These observations were presumed to explain the association between mild hyperhomocysteinemia and the diseases described below.</p><p class="headingAnchor" id="H8"><span class="h2">Vascular disease</span><span class="headingEndMark"> — </span>Elevated homocysteine levels have been associated with an increased risk of cardiovascular and cerebrovascular disease. However, unlike modifiable risk factors such as hypertension, hypercholesterolemia, smoking, and diabetes, it has not been shown that lowering homocysteine prevents cardiovascular events [<a href="#rid44">44</a>]. (See <a class="local">'Patients with cardiovascular disease or venous thromboembolism'</a> below and  <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a>.)</p><p>The association of elevated homocysteine with cardiovascular disease and stroke was illustrated by a meta-analysis that evaluated data from 12 prospective studies, involving 1855 coronary heart disease (CHD) events and 463 stroke events [<a href="#rid45">45</a>]. After adjustment for known cardiovascular risk factors, a 25 percent lower homocysteine level (approximately 3 micromol/L) was associated with a lower risk of ischemic heart disease risk (odds ratio [OR] 0.89, 95% CI 0.83-0.86) and stroke (OR 0.81, 95% CI 0.69-0.95). Another meta-analysis performed for the US Preventive Services Task Force (USPSTF) specifically examined the issue of whether or not homocysteine levels add predictive value when estimating the risk of new-onset CHD [<a href="#rid46">46</a>]. The analysis found that, independent of Framingham risk factors, each 5 micromol/L higher homocysteine level was associated with a 20 percent greater risk of CHD. Hyperhomocysteinemia has also been associated with lower-extremity peripheral arterial disease and heart failure [<a href="#rid47">47,48</a>].</p><p>Genetic studies, whereby individuals with genetically determined elevations in plasma homocysteine are examined, have reported inconsistent findings about risk for cardiovascular disease [<a href="#rid49">49-51</a>]. As an example, in one meta-analysis of 40 observational studies involving 11,162 patients who were homozygous for the thermolabile variant of methylene tetrahydrofolate reductase (<em>MTHFR</em>, which produces higher homocysteine levels) and 12,758 matched controls, the <em>MTHFR</em> TT genotype was associated with a higher risk for CHD (OR 1.16, 95% CI 1.05-1.28) [<a href="#rid49">49</a>]. However, a subsequent meta-analysis of genome-wide association studies including 31,400 cases and 92,927 controls found no association between a genetic risk score of homocysteine-regulating genes and CHD, although plasma homocysteine levels were lacking in most individuals [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H2236501998"><span class="h2">Venous thromboembolism</span><span class="headingEndMark"> — </span>Hyperhomocysteinemia has been associated with venous thromboembolism (VTE) in some but not all studies [<a href="#rid52">52-58</a>].</p><p>Meta-analyses of case-control studies have found an odds ratio of 2.5 to 3.0 for VTE in patients with markedly elevated homocysteine levels of more than two standard deviations above the mean value of control groups [<a href="#rid53">53,54</a>]. Moderate hyperhomocysteinemia (15 to 30 micromol/L) may also be a risk marker for recurrent VTE. This was reported in a multicenter study in which patients with a single episode of idiopathic VTE were prospectively followed after discontinuation of oral anticoagulants [<a href="#rid55">55</a>]. Recurrent VTE was significantly more likely in the 66 patients with hyperhomocysteinemia than in the 198 patients with normal homocysteine levels (18.2 versus 8.1 percent).</p><p>Additional research, however, has concluded that perceived associations between mild hyperhomocysteinemia and VTE may have been due to confounding [<a href="#rid56">56-58</a>]. In a large case-control study of over 3000 individuals, for example, mild hyperhomocysteinemia was associated with venous thrombosis in models adjusted for age and sex but not after also controlling for body mass index (BMI) and smoking status [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H1523434067"><span class="h2">Obstetric complications</span><span class="headingEndMark"> — </span>An early report linked the thermolabile variant of <em>MTHFR</em> to obstetric complications such as severe preeclampsia, abruptio placentae, fetal growth restriction, neural tube defects, and stillbirth [<a href="#rid59">59,60</a>]. However, a 2006 meta-analysis of 26 studies of 2120 women with unexplained recurrent pregnancy loss and 2949 controls did not find that the <em>MTHFR</em> C677T genotype was a risk factor for this outcome, except in a Chinese population [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H1526520681"><span class="h2">Other</span><span class="headingEndMark"> — </span>Hyperhomocysteinemia is also associated with other disorders:</p><p class="bulletIndent1"><span class="glyph">●</span>Osteoporosis – High homocysteine levels in adults have been associated with osteoporotic fractures in some [<a href="#rid62">62-64</a>], but not all [<a href="#rid65">65</a>], studies.</p><p></p><p class="bulletIndent1">In a trial of homocysteine-lowering therapy with folate and B12 in adults at high risk for cardiovascular disease, there was no reduction in vertebral or nonvertebral fractures, although baseline homocysteine levels were not elevated in the study population [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dementia – Hyperhomocysteinemia is associated with higher rates of dementia [<a href="#rid67">67</a>]; however, there is no convincing evidence that lowering homocysteine levels prevents or treats dementia [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/z/d/html/5079.html" rel="external">"Risk factors for cognitive decline and dementia", section on 'Homocysteine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Several studies report an association of elevated homocysteine with cognitive impairment in Parkinson disease [<a href="#rid69">69,70</a>].</p><p></p><p class="headingAnchor" id="H2456829189"><span class="h1">DECISION TO TEST</span><span class="headingEndMark"> — </span>In general, we only measure serum homocysteine in patients suspected of having homocystinuria but not in other clinical settings.</p><p class="headingAnchor" id="H952837209"><span class="h2">Patients with suspected homocystinuria</span><span class="headingEndMark"> — </span>We measure homocysteine levels in patients with suspected homocystinuria and in first-degree relatives of patients with homocystinuria.</p><p>Homocystinuria is suspected in children and adolescents with characteristic physical findings, developmental delay, or cardiovascular disease or thromboembolism. It is occasionally diagnosed in young adults [<a href="#rid71">71</a>]. Patients with homocystinuria have markedly elevated serum and urine homocysteine.</p><p>Homocystinuria is a rare autosomal recessive disorder. Clinical manifestations of homocystinuria include developmental delay, Marfanoid appearance, osteoporosis, ocular abnormalities (ectopia lentis), thromboembolic disease, and severe premature atherosclerosis. Routine newborn screening can detect homocystinuria but is not universally available.</p><p class="headingAnchor" id="H3163022070"><span class="h2">Patients with cardiovascular disease or venous thromboembolism</span><span class="headingEndMark"> — </span>Interventions to lower homocysteine have <strong>not</strong> been shown to prevent cardiovascular disease or venous thromboembolism (VTE) [<a href="#rid44">44,72-77</a>]. In addition, as outlined above, the association between mild hyperhomocysteinemia and VTE may be due to confounding. Accordingly, we generally do <strong>not</strong> measure homocysteine levels in patients with vascular disease or VTE. Our approach is based upon trial evidence that lowering homocysteine levels with vitamin supplementation does not improve clinical outcomes. However, these trials were conducted in countries with <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> fortification of the food supply and primarily among participants who were not required to have elevated plasma homocysteine at baseline. In addition, these trials were designed to lower homocysteine concentrations with folic acid, but participants with normal folic acid levels were not excluded [<a href="#rid15">15</a>].</p><p>Lowering homocysteine levels has not been shown to prevent future cardiovascular events, with the possible exception of stroke [<a href="#rid44">44,72,74</a>]. The best data come from a meta-analysis of 15 randomized trials including 71,422 participants which found that, compared with placebo, homocysteine-lowering therapy (folate, vitamin B12, and/or vitamin B6) failed to reduce the risk of myocardial infarction (7.1 versus 6.0 percent), all-cause mortality (11.7 versus 12.3 percent), or serious adverse events (8.3 versus 8.5 percent) [<a href="#rid44">44</a>]. Homocysteine-lowering therapy modestly reduced the incidence of stroke compared with placebo (4.3 versus 5.1 percent), although this finding was largely influenced by a single Chinese study [<a href="#rid78">78</a>].</p><p>As with cardiovascular disease, lowering homocysteine has not been shown to reduce rates of recurrent VTE. The best data come from a randomized trial of homocysteine-lowering with daily B vitamins (<a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> 5 mg, vitamin B6 50 mg, vitamin B12 0.4 mg) in 701 patients with a first episode of VTE [<a href="#rid76">76</a>]. There was no statistically significant reduction in recurrent VTE in patients treated with B vitamins (hazard ratio [HR] 0.84, 95% CI 0.56-1.26). There was also no reduction in recurrent VTE in the 360 patients with baseline homocysteine levels above the 75<sup>th</sup> percentile (HR 1.14, 95% CI 0.65-1.98), or in the 341 patients with normal homocysteine levels (HR 0.58, 95% CI 0.31-1.07). A post hoc subgroup analysis of a second trial reached similar conclusions [<a href="#rid77">77</a>].</p><p class="headingAnchor" id="H1887215670"><span class="h2">Patients without known vascular disease</span><span class="headingEndMark"> — </span>Patients without known vascular disease may ask to have their homocysteine levels checked as part of risk stratification for cardiovascular disease. Given the lack of evidence for benefit from lowering elevated homocysteine levels in patients with established cardiovascular disease, we do not measure homocysteine levels in patients without known vascular disease.</p><p class="headingAnchor" id="H188577083"><span class="h1">LABORATORY MEASUREMENT OF HOMOCYSTEINE</span><span class="headingEndMark"> — </span>Sensitive assays allow quantification of the total homocysteine concentration; approximately 75 to 85 percent is protein-bound and 15 to 25 percent is in acid-soluble free forms [<a href="#rid79">79</a>]. Processing of specimens for homocysteine measurement requires cooling the specimen in wet ice and prompt transfer to the laboratory to minimize delays in processing. Delays in processing contribute to falsely elevated homocysteine levels [<a href="#rid80">80</a>].</p><p>Normal homocysteine concentrations range between 5 and 15 micromol/L. Hyperhomocysteinemia has been classified as follows [<a href="#rid81">81</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Moderate (15 to 30 micromol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Intermediate (30 to 100 micromol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Severe (&gt;100 micromol/L)</p><p></p><p class="headingAnchor" id="H2332790403"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>As described above, the available evidence suggests <strong>not</strong> testing for or treating hyperhomocysteinemia unless homocystinuria is suspected or confirmed. In the rare patient with severe hyperhomocysteinemia associated with homocystinuria, we recommend referral to both a specialist in metabolic diseases and a nutritionist. (See <a class="local">'Decision to test'</a> above.)</p><p>The majority of hyperhomocysteinemia is caused by low levels of folate and vitamin B12 in patients with or without the thermolabile variant of methylene tetrahydrofolate reductase (<em>MTHFR</em>). (See <a class="local">'Etiology of hyperhomocysteinemia'</a> above.)</p><p>Correcting nutritional inadequacy of <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> and vitamin B12 will lower homocysteine levels in most patients [<a href="#rid82">82</a>]. A diet rich in fruits, vegetables, and low-fat dairy products and low in saturated and total fat can also lower serum homocysteine when compared with a diet relatively low in fruits, vegetables and dairy products, with a fat content typical of United States consumption [<a href="#rid83">83</a>].</p><p>In many countries, grains are fortified with <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a>, which leads to higher folate levels across the population. As an example, mandatory folic acid fortification of cereal grains in the United States led to a more than twofold increase in mean serum folate levels in a nationally representative survey [<a href="#rid84">84</a>].</p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Homocysteine is an intermediary amino acid formed by the conversion of methionine to cysteine. Elevations in plasma homocysteine are common, occurring in 5 to 7 percent of the population. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology of hyperhomocysteinemia</strong> – Homocysteine is metabolized by one of two pathways: transsulfuration and remethylation  (<a class="graphic graphic_figure graphicRef118333" href="/z/d/graphic/118333.html" rel="external">figure 1</a>). Vitamins are necessary in the metabolism of homocysteine. Elevations in plasma homocysteine levels can result from genetic factors, most commonly a thermolabile variant of methylene tetrahydrofolate reductase (<em>MTHFR</em>) with reduced enzymatic activity (T mutation); vitamin deficiencies, specifically deficiency of folate, vitamin B6, or vitamin B12; chronic kidney disease, which can increase homocysteine levels due to decreased renal removal and impaired metabolism; certain drugs, including fibrates, nicotinic acid, <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>, and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>; and cigarette smoking. (See <a class="local">'Etiology of hyperhomocysteinemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decision to test</strong> – In general, we only measure serum homocysteine in patients suspected of having homocystinuria but not in other clinical settings. (See <a class="local">'Decision to test'</a> above and <a class="local">'Laboratory measurement of homocysteine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Homocystinuria</strong> – Homocystinuria, a rare condition detected by newborn screening in many regions, presents in children and adolescents with developmental delay, Marfanoid appearance, osteoporosis, ocular abnormalities (ectopia lentis), thromboembolic disease, severe premature atherosclerosis, and extreme elevations in plasma homocysteine. In the rare patient with severe hyperhomocysteinemia associated with homocystinuria, we recommend referral to both a specialist in metabolic diseases and a nutritionist. (See <a class="local">'Decision to test'</a> above and <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease associations</strong> – Moderately elevated homocysteine levels have been associated with an increased risk of cardiovascular and cerebrovascular disease, venous thromboembolic disease, and obstetric complications. In experimental studies, homocysteine has primary atherogenic and prothrombotic properties, suggesting a possible mechanism for these associations. (See <a class="local">'Disease associations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limited role for treatment</strong> – Despite some limitations, clinical trials have generally found that reducing levels of homocysteine with B vitamin supplementation does not prevent cardiovascular disease or reduce the incidence of recurrent venous thromboembolism (VTE) or arterial thrombosis. Thus, we suggest <strong>not</strong> testing for or treating hyperhomocysteinemia (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>), unless homocystinuria is suspected or confirmed. (See <a class="local">'Patients with cardiovascular disease or venous thromboembolism'</a> above.)</p><p></p><p class="headingAnchor" id="H1581169171"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David Kang, MD, PhD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989; 114:473.</a></li><li><a class="nounderline abstract_t">McCully KS. Homocysteine and vascular disease. Nat Med 1996; 2:386.</a></li><li><a class="nounderline abstract_t">Kang SS, Wong PW, Susmano A, et al. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48:536.</a></li><li class="breakAll">https://www.cdc.gov/genomics/population/genvar/frequencies/mthfr.htm.</li><li><a class="nounderline abstract_t">Guttormsen AB, Ueland PM, Nesthus I, et al. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (&gt; or = 40 micromol/liter). The Hordaland Homocysteine Study. J Clin Invest 1996; 98:2174.</a></li><li><a class="nounderline abstract_t">Harmon DL, Woodside JV, Yarnell JW, et al. The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. QJM 1996; 89:571.</a></li><li><a class="nounderline abstract_t">Kluijtmans LA, Young IS, Boreham CA, et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 2003; 101:2483.</a></li><li><a class="nounderline abstract_t">de Bree A, Verschuren WM, Bjørke-Monsen AL, et al. Effect of the methylenetetrahydrofolate reductase 677C--&gt;T mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample. Am J Clin Nutr 2003; 77:687.</a></li><li><a class="nounderline abstract_t">Robinson K, Arheart K, Refsum H, et al. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation 1998; 97:437.</a></li><li><a class="nounderline abstract_t">Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279:359.</a></li><li><a class="nounderline abstract_t">Voutilainen S, Rissanen TH, Virtanen J, et al. Low dietary folate intake is associated with an excess incidence of acute coronary events: The Kuopio Ischemic Heart Disease Risk Factor Study. Circulation 2001; 103:2674.</a></li><li><a class="nounderline abstract_t">Vermeulen EG, Stehouwer CD, Twisk JW, et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000; 355:517.</a></li><li><a class="nounderline abstract_t">Selhub J, Jacques PF, Wilson PW, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270:2693.</a></li><li><a class="nounderline abstract_t">Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993; 57:47.</a></li><li><a class="nounderline abstract_t">Kang SS, Rosenson RS. Analytic Approaches for the Treatment of Hyperhomocysteinemia and Its Impact on Vascular Disease. Cardiovasc Drugs Ther 2018; 32:233.</a></li><li><a class="nounderline abstract_t">Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999; 340:1449.</a></li><li><a class="nounderline abstract_t">Desouza C, Keebler M, McNamara DB, Fonseca V. Drugs affecting homocysteine metabolism: impact on cardiovascular risk. Drugs 2002; 62:605.</a></li><li><a class="nounderline abstract_t">Rosenson RS. Antiatherothrombotic effects of nicotinic acid. Atherosclerosis 2003; 171:87.</a></li><li><a class="nounderline abstract_t">Dierkes J, Westphal S, Luley C. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. Expert Opin Drug Saf 2004; 3:101.</a></li><li><a class="nounderline abstract_t">Zhang Q, Li S, Li L, et al. Metformin Treatment and Homocysteine: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2016; 8.</a></li><li><a class="nounderline abstract_t">Bazzano LA, He J, Muntner P, et al. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 2003; 138:891.</a></li><li><a class="nounderline abstract_t">Poddar R, Sivasubramanian N, DiBello PM, et al. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular disease. Circulation 2001; 103:2717.</a></li><li><a class="nounderline abstract_t">Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17:2074.</a></li><li><a class="nounderline abstract_t">Al-Obaidi MK, Philippou H, Stubbs PJ, et al. Relationships between homocysteine, factor VIIa, and thrombin generation in acute coronary syndromes. Circulation 2000; 101:372.</a></li><li><a class="nounderline abstract_t">Nappo F, De Rosa N, Marfella R, et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999; 281:2113.</a></li><li><a class="nounderline abstract_t">Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91:2873.</a></li><li><a class="nounderline abstract_t">Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986; 77:1909.</a></li><li><a class="nounderline abstract_t">Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88:1906.</a></li><li><a class="nounderline abstract_t">Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993; 92:1381.</a></li><li><a class="nounderline abstract_t">Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992; 79:2930.</a></li><li><a class="nounderline abstract_t">Mansoor MA, Bergmark C, Svardal AM, et al. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease. Homocysteine and peripheral vascular disease. Arterioscler Thromb Vasc Biol 1995; 15:232.</a></li><li><a class="nounderline abstract_t">Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77:1370.</a></li><li><a class="nounderline abstract_t">Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91:308.</a></li><li><a class="nounderline abstract_t">McCully KS, Carvalho AC. Homocysteine thiolactone, N-homocysteine thiolactonyl retinamide, and platelet aggregation. Res Commun Chem Pathol Pharmacol 1987; 56:349.</a></li><li><a class="nounderline abstract_t">Stühlinger MC, Tsao PS, Her JH, et al. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001; 104:2569.</a></li><li><a class="nounderline abstract_t">Woo KS, Chook P, Lolin YI, et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96:2542.</a></li><li><a class="nounderline abstract_t">Kanani PM, Sinkey CA, Browning RL, et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 1999; 100:1161.</a></li><li><a class="nounderline abstract_t">Tawakol A, Omland T, Gerhard M, et al. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95:1119.</a></li><li><a class="nounderline abstract_t">McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56:111.</a></li><li><a class="nounderline abstract_t">Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58:731.</a></li><li><a class="nounderline abstract_t">Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med 1974; 291:537.</a></li><li><a class="nounderline abstract_t">Rolland PH, Friggi A, Barlatier A, et al. Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation 1995; 91:1161.</a></li><li><a class="nounderline abstract_t">Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A 1994; 91:6369.</a></li><li><a class="nounderline abstract_t">Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2017; 8:CD006612.</a></li><li><a class="nounderline abstract_t">Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288:2015.</a></li><li><a class="nounderline abstract_t">Humphrey LL, Fu R, Rogers K, et al. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc 2008; 83:1203.</a></li><li><a class="nounderline abstract_t">Cheng SW, Ting AC, Wong J. Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease. Ann Vasc Surg 1997; 11:217.</a></li><li><a class="nounderline abstract_t">Vasan RS, Beiser A, D'Agostino RB, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA 2003; 289:1251.</a></li><li><a class="nounderline abstract_t">Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C--&gt;T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002; 288:2023.</a></li><li><a class="nounderline abstract_t">Kohara K, Fujisawa M, Ando F, et al. MTHFR gene polymorphism as a risk factor for silent brain infarcts and white matter lesions in the Japanese general population: The NILS-LSA Study. Stroke 2003; 34:1130.</a></li><li><a class="nounderline abstract_t">van Meurs JB, Pare G, Schwartz SM, et al. Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease. Am J Clin Nutr 2013; 98:668.</a></li><li><a class="nounderline abstract_t">den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334:759.</a></li><li><a class="nounderline abstract_t">Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998; 158:2101.</a></li><li><a class="nounderline abstract_t">den Heijer M, Rosendaal FR, Blom HJ, et al. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998; 80:874.</a></li><li><a class="nounderline abstract_t">Eichinger S, Stümpflen A, Hirschl M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998; 80:566.</a></li><li><a class="nounderline abstract_t">Lijfering WM, Coppens M, van de Poel MH, et al. The risk of venous and arterial thrombosis in hyperhomocysteinaemia is low and mainly depends on concomitant thrombophilic defects. Thromb Haemost 2007; 98:457.</a></li><li><a class="nounderline abstract_t">Lijfering WM, Veeger NJ, Brouwer JL, van der Meer J. The risk of venous and arterial thrombosis in hyperhomocysteinemic subjects may be a result of elevated factor VIII levels. Haematologica 2007; 92:1703.</a></li><li><a class="nounderline abstract_t">Ospina-Romero M, Cannegieter SC, den Heijer M, et al. Hyperhomocysteinemia and Risk of First Venous Thrombosis: The Influence of (Unmeasured) Confounding Factors. Am J Epidemiol 2018; 187:1392.</a></li><li><a class="nounderline abstract_t">Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340:9.</a></li><li><a class="nounderline abstract_t">Hague WM. Homocysteine and pregnancy. Best Pract Res Clin Obstet Gynaecol 2003; 17:459.</a></li><li><a class="nounderline abstract_t">Ren A, Wang J. Methylenetetrahydrofolate reductase C677T polymorphism and the risk of unexplained recurrent pregnancy loss: a meta-analysis. Fertil Steril 2006; 86:1716.</a></li><li><a class="nounderline abstract_t">van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004; 350:2033.</a></li><li><a class="nounderline abstract_t">McLean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004; 350:2042.</a></li><li><a class="nounderline abstract_t">Dhonukshe-Rutten RA, Pluijm SM, de Groot LC, et al. Homocysteine and vitamin B12 status relate to bone turnover markers, broadband ultrasound attenuation, and fractures in healthy elderly people. J Bone Miner Res 2005; 20:921.</a></li><li><a class="nounderline abstract_t">Gerdhem P, Ivaska KK, Isaksson A, et al. Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women. J Bone Miner Res 2007; 22:127.</a></li><li><a class="nounderline abstract_t">Sawka AM, Ray JG, Yi Q, et al. Randomized clinical trial of homocysteine level lowering therapy and fractures. Arch Intern Med 2007; 167:2136.</a></li><li><a class="nounderline abstract_t">Smith AD, Refsum H, Bottiglieri T, et al. Homocysteine and Dementia: An International Consensus Statement. J Alzheimers Dis 2018; 62:561.</a></li><li><a class="nounderline abstract_t">Clarke R, Bennett D, Parish S, et al. Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals. Am J Clin Nutr 2014; 100:657.</a></li><li><a class="nounderline abstract_t">Licking N, Murchison C, Cholerton B, et al. Homocysteine and cognitive function in Parkinson's disease. Parkinsonism Relat Disord 2017; 44:1.</a></li><li><a class="nounderline abstract_t">Christine CW, Auinger P, Joslin A, et al. Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease. Mov Disord 2018; 33:762.</a></li><li><a class="nounderline abstract_t">Narayanan D, Luvai A, Barski R, Sharma R. Stroke in a young man. BMJ 2013; 347:f4484.</a></li><li><a class="nounderline abstract_t">Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 2006; 296:2720.</a></li><li><a class="nounderline abstract_t">Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007; 369:1876.</a></li><li><a class="nounderline abstract_t">Miller ER 3rd, Juraschek S, Pastor-Barriuso R, et al. Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels. Am J Cardiol 2010; 106:517.</a></li><li><a class="nounderline abstract_t">Lee M, Hong KS, Chang SC, Saver JL. Efficacy of homocysteine-lowering therapy with folic Acid in stroke prevention: a meta-analysis. Stroke 2010; 41:1205.</a></li><li><a class="nounderline abstract_t">den Heijer M, Willems HP, Blom HJ, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood 2007; 109:139.</a></li><li><a class="nounderline abstract_t">Ray JG, Kearon C, Yi Q, et al. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. Ann Intern Med 2007; 146:761.</a></li><li><a class="nounderline abstract_t">Li J, Huo Y, Qin X, et al. Efficacy of folic acid supplementation in primary prevention of stroke among adults with hypertension in China. JAMA 2015; 313:1325.</a></li><li><a class="nounderline abstract_t">Kang SS, Wong PW. Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia. Atherosclerosis 1996; 119:135.</a></li><li><a class="nounderline abstract_t">Rosenson RS, Tangney CC. Preanalytical sources of measurement error: the conundrum of the homocysteine hypothesis. Atherosclerosis 2007; 194:520.</a></li><li><a class="nounderline abstract_t">Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992; 12:279.</a></li><li><a class="nounderline abstract_t">Kang SS. Treatment of hyperhomocyst(e)inemia: physiological basis. J Nutr 1996; 126:1273S.</a></li><li><a class="nounderline abstract_t">Appel LJ, Miller ER 3rd, Jee SH, et al. Effect of dietary patterns on serum homocysteine: results of a randomized, controlled feeding study. Circulation 2000; 102:852.</a></li><li><a class="nounderline abstract_t">Dietrich M, Brown CJ, Block G. The effect of folate fortification of cereal-grain products on blood folate status, dietary folate intake, and dietary folate sources among adult non-supplement users in the United States. J Am Coll Nutr 2005; 24:266.</a></li></ol></div><div id="topicVersionRevision">Topic 6837 Version 52.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2681479" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8597939" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Homocysteine and vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1998339" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1998339" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8903338" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (&gt;or = 40 micromol/liter). The Hordaland Homocysteine Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8935478" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12642343" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12600862" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effect of the methylenetetrahydrofolate reductase 677C--&gt;T mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9490237" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9459468" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11390336" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Low dietary folate intake is associated with an excess incidence of acute coronary events: The Kuopio Ischemic Heart Disease Risk Factor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10683000" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8133587" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Vitamin status and intake as primary determinants of homocysteinemia in an elderly population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8416664" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29679304" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Analytic Approaches for the Treatment of Hyperhomocysteinemia and Its Impact on Vascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10320382" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The effect of folic acid fortification on plasma folate and total homocysteine concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11893229" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Drugs affecting homocysteine metabolism: impact on cardiovascular risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14642410" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Antiatherothrombotic effects of nicotinic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15006716" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27941660" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Metformin Treatment and Homocysteine: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12779299" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11390343" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9351374" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10653827" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Relationships between homocysteine, factor VIIa, and thrombin generation in acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10367822" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8390492" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3519683" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1661291" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8376590" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1316788" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7749831" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease. Homocysteine and peripheral vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3514679" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8380812" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3628965" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Homocysteine thiolactone, N-homocysteine thiolactonyl retinamide, and platelet aggregation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11714652" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9355891" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10484535" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9054838" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5792556" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/821969" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4212055" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Homocystinemia. Vascular injury and arterial thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7850955" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8022789" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28816346" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Homocysteine-lowering interventions for preventing cardiovascular events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12387654" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18990318" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9140594" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12633186" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12387655" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : MTHFR 677C--&gt;T polymorphism and risk of coronary heart disease: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12690212" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : MTHFR gene polymorphism as a risk factor for silent brain infarcts and white matter lesions in the Japanese general population: The NILS-LSA Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23824729" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8592549" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9801176" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9869152" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hyperhomocysteinemia and venous thrombosis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9798970" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17721631" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The risk of venous and arterial thrombosis in hyperhomocysteinaemia is low and mainly depends on concomitant thrombophilic defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18055997" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The risk of venous and arterial thrombosis in hyperhomocysteinemic subjects may be a result of elevated factor VIII levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29370361" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Hyperhomocysteinemia and Risk of First Venous Thrombosis: The Influence of (Unmeasured) Confounding Factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9878639" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Increased frequency of genetic thrombophilia in women with complications of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12787538" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Homocysteine and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17074326" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Methylenetetrahydrofolate reductase C677T polymorphism and the risk of unexplained recurrent pregnancy loss: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15141041" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Homocysteine levels and the risk of osteoporotic fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15141042" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Homocysteine as a predictive factor for hip fracture in older persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15883631" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Homocysteine and vitamin B12 status relate to bone turnover markers, broadband ultrasound attenuation, and fractures in healthy elderly people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17032146" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17954810" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Randomized clinical trial of homocysteine level lowering therapy and fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29480200" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Homocysteine and Dementia: An International Consensus Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24965307" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28807493" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Homocysteine and cognitive function in Parkinson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29508904" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Vitamin B12 and Homocysteine Levels Predict Different Outcomes in Early Parkinson's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23857996" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Stroke in a young man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17164458" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17544768" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Efficacy of folic acid supplementation in stroke prevention: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20691310" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20413740" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Efficacy of homocysteine-lowering therapy with folic Acid in stroke prevention: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16960155" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470822" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Efficacy of folic acid supplementation in primary prevention of stroke among adults with hypertension in China</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8808490" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17109864" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Preanalytical sources of measurement error: the conundrum of the homocysteine hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1503807" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8642469" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Treatment of hyperhomocyst(e)inemia: physiological basis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10952952" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Effect of dietary patterns on serum homocysteine: results of a randomized, controlled feeding study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16093404" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The effect of folate fortification of cereal-grain products on blood folate status, dietary folate intake, and dietary folate sources among adult non-supplement users in the United States.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
